Hyundai Bioscience Co., Ltd. (KOSDAQ: 048410)

Market Cap	562.25B
Revenue (ttm)	9.24B
Net Income (ttm)	-6.57B
Shares Out	39.82M
EPS (ttm)	-165.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	322,925
Open	16,600
Previous Close	16,600
Day's Range	15,780 - 16,720
52-Week Range	14,610 - 35,100
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Hyundai Bioscience

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.

• Industry: Perfumes, Cosmetics, and Other Toilet Preparations
• Founded: 2000
• Employees: 63
• Stock Exchange: KOSDAQ
• Ticker Symbol: 048410

Financial Performance

In 2023, Hyundai Bioscience's revenue was 9.48 billion, an increase of 20.76% compared to the previous year's 7.85 billion. Losses were -14.50 billion, -8.27% less than in 2022.